Profitability
Weight: 25%
B-
68
- 5yr Avg ROIC 22.9%
- Operating Margin Trend -6.40 pp/yr
CORT
Corcept Therapeutics Incorporated
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
Capital Efficiency
Weight: 15%
A
88
- 5yr Avg ROE 21.4%
- 5yr Share-Count CAGR -0.7%
Growth Quality
Weight: 25%
B-
69
- 5yr Revenue CAGR 16.6%
- 5yr EPS CAGR -0.7%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
A+
97
- 5yr FCF Margin 29.9%
- 5yr FCF/NI Conversion 1.34x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -5.36x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 42.05
Stability
Weight: 5%
C+
59
- EPS Volatility (σ/μ) 0.38
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 4
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.4 of 4 gurus held; 2 added; 2 trimmed.
- Holders
- 4
- Avg Δ position
- +42.8%
- New buys
- 0
- Full exits
- 0
- Greenblatt increased +236%
- Wood decreased -89%
- Dalio increased +50%